Loading
Life sciences · Journal article
Roentgen Ray Review · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Current trends in the United States indicate an increasing population of individuals who identify as transgender. Transgender patients often delay preventive health care, with breast cancer screening rates falling behind those of cisgender patients. Furthermore, within the transgender male population, there is limited literature on the risk of breast cancer among those receiving androgen therapy. Awareness of both the breast cancer risk in the transgender male population and current screening guidelines helps radiologists ensure that transgender patients receive optimal breast care. We present two cases of patient-detected invasive breast malignancy in transgender men, both of whom were receiving gender-affirming hormone therapy with testosterone, and review breast cancer screening guidelines for transgender male patients and potential barriers to care.